QN523 exhibits potent cytotoxicity in pancreatic cancer cell lines (IC50 of 0.11 μM in MIA PaCa-2 cells) and significantly delays growth of MIA PaCa-2 xenograft in NOD/SCID mice without systemic toxicity.

ML901 is a specific reagent that hijacks a single aminoacyl transfer RNA (tRNA) synthetases (aaRSs) in the malaria parasite Plasmodium falciparum. ML901 inhibits the growth of the malaria parasite Plasmodium falciparum in vitro and in animals but was not toxic to human cells.

ERX-41 is a potent therapeutic agent targeting lysosomal acid lipase A (LIPA) and shows the mechanism of action (disruption of protein folding and induction of ER stress) that may have utility in treating patients with TNBC or other multiple solid tumors.

CID661578 is a potent inducer of β-cell regeneration, which boosts protein synthesis and regeneration by blocking MNK2 from binding eIF4G in the translation initiation complex at the mRNA cap.

NKTP-3 is a potent, selective, biostable, and cell-permeable cyclic d-peptide that targets NRP1 and KRASG12D with binding affinity of 116.28 nM and 50.34 nM, respectively. NKTP-3 shows good biostability and a strong cellular uptake ability and further demonstrated its antitumor effect on lung cancer with the KRASG12D mutation in vitro and in vivo.

IGUANA-1 is an isoform-selective guanidinyl antagonists of ALDHs, which exhibits proteome-wide target specificity and selectively blocks the growth of colon cancer spheroids and organoids.

S3-15 selectively interrupts soluble RANKL-RANK interaction and without interfering with the membrane RANKL-RANK interaction. S3-15 exhibits anti-osteoporotic effects without causing immunosuppression.

JZ128 is a potential, irreversible, selective inhibitor of PKN3 with IC50  of 120 nM and shows a narrow kinome inhibition spectrum. JZ128 is used as a tool compound to identify novel potential PKN3 substrates.

Compound 16 (UNC-CA94) is a reversible inhibitor of PKN3 with IC50 of 14 nM. Compound 16 (UNC-CA94) is a potential tool compound to study the cell biology of PKN3.

Jun9-62-2R (dichloroacetamide) is a selective covalent Mpro inhibitor with IC50 of 0.43 μM and viral replication with EC50 of 2.05 μM in Caco2-hACE2 cells. Jun9-62-2R (dichloroacetamide) is highly selective toward Mpro and does not inhibit the host calpain I, cathepsins B, K, L, caspase-3, and trypsin. The widely used antibiotic chloramphenicol contains the dichloroacetamide, suggesting Jun9-62-2R might be tolerated in vivo.

D11 is a potent and selective inhibitor of protein kinase CK2 with Ki of 5 nM.

Comopound X1 (Xist) binds the non-coding RNA prototype Xist, specifically the RepA motif, with Kd of 0.4 μM. X1 binding reduces the conformational space of RepA, displaces cognate interacting protein factors (PRC2 and SPEN), suppresses histone H3K27 trimethylation, and blocks initiation of X-chromosome inactivation.

WC36 is a novel nonlipidic inhibitor of the lipid-SH2 domain interaction. WC36 is effective against RAS-mutated HL-60 AML cells that shows de novo resistance to entospletinib.

Sitagliptin, also known as MK-0431, is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts. Sitagliptin is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.

Tematropium(CDDD3602) is a soft anticholinergics.

CDC801 is a potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α) inhibitor with IC50 of 1.1 μM and 2.5 μM, respectively.

APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD)[1].